Fractyl Health, Inc. Common Stock
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a GUTS research report →
Companyfractyl.com
Fractyl Health, Inc. , a metabolic therapeutics company, develops therapies for the treatment of type 2 diabetes (T2D) and obesity. The company develops Revita DMR System (Revita), an outpatient procedural therapy designed to durably modify duodenal dysfunction, a pathologic consequence of a high fat and high sugar diet, which can initiate T2D and obesity in humans.
- CEO
- Harith Rajagopalan
- IPO
- 2024
- Employees
- 107
- HQ
- Lexington, MA, US
Price Chart
Valuation
- Market Cap
- $66.51M
- P/E
- -0.65
- P/S
- 0.00
- P/B
- 3.27
- EV/EBITDA
- -0.70
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -4573.89%
- ROIC
- -104.22%
Growth & Income
- Revenue
- $0 · -100.00%
- Net Income
- $-140,954,000 · -105.19%
- EPS
- $-1.86 · -14.81%
- Op Income
- $-96,816,000
- FCF YoY
- -35.07%
Performance & Tape
- 52W High
- $3.03
- 52W Low
- $0.38
- 50D MA
- $0.58
- 200D MA
- $1.12
- Beta
- 2.11
- Avg Volume
- 2.33M
Get TickerSpark's AI analysis on GUTS
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jan 12, 26 | Smith Weber Lara | other | 1,036,800 |
| Jan 12, 26 | Smith Weber Lara | other | 0 |
| Dec 15, 25 | Toomey Sarah | other | 743,913 |
| Dec 15, 25 | Caplan Jay David | other | 845,226 |
| Dec 15, 25 | Rajagopalan Harith | other | 2,486,302 |
| Dec 4, 25 | Rajagopalan Harith | buy | 10,416 |
| Sep 2, 25 | Thompson Christopher Charles | other | 45,000 |
| Sep 2, 25 | Thompson Christopher Charles | other | 20,969 |
| Sep 2, 25 | Sheffield Ian | other | 45,000 |
| Sep 2, 25 | Sheffield Ian | other | 0 |
Our GUTS Coverage
We haven't published any research on GUTS yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate GUTS Report →